Cargando…

Tumor mutational burden presents limiting effects on predicting the efficacy of immune checkpoint inhibitors and prognostic assessment in adrenocortical carcinoma

BACKGROUND: Adrenocortical carcinoma (ACC) is a highly malignant urologic cancer and tends to metastasize. Although immune checkpoint inhibitors (ICIs) bring a glimmer of light to conquer ACC, only a fraction of patients have benefit from ICIs treatment. It is well known that tumor mutational burden...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xu, Fangshi, Guan, Yibing, Zhang, Peng, Xue, Li, Ma, Yubo, Gao, Mei, Chong, Tie, Ren, Bin-Cheng
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2022
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107278/ https://www.ncbi.nlm.nih.gov/pubmed/35568842 http://dx.doi.org/10.1186/s12902-022-01017-3

Ejemplares similares

Bioinformatic analyses and experimental validation of the role of m6A RNA methylation regulators in progression and prognosis of adrenocortical carcinoma
por: Xu, Fangshi, et al.
Publicado: (2021)

Bioinformatic screening and identification of downregulated hub genes in adrenocortical carcinoma
por: Xu, Fangshi, et al.
Publicado: (2020)

Abnormal expression and the significant prognostic value of aquaporins in clear cell renal cell carcinoma
por: Li, Mingrui, et al.
Publicado: (2022)

The roles of ferroptosis regulatory gene SLC7A11 in renal cell carcinoma: A multi‐omics study
por: Xu, Fangshi, et al.
Publicado: (2021)

The prognostic value of circulating tumour cells (CTCs) and CTC white blood cell clusters in patients with renal cell carcinoma
por: Guan, Yibing, et al.
Publicado: (2021)

A New Prognostic Risk Score: Based on the Analysis of Autophagy-Related Genes and Renal Cell Carcinoma
por: He, Minxin, et al.
Publicado: (2022)

Corrigendum: A New Prognostic Risk Score: Based on the Analysis of Autophagy-Related Genes and Renal Cell Carcinoma
por: He, Minxin, et al.
Publicado: (2022)

The effect of a novel glycolysis-related gene signature on progression, prognosis and immune microenvironment of renal cell carcinoma
por: Xu, Fangshi, et al.
Publicado: (2020)

Identification of key genes and functions of circulating tumor cells in multiple cancers through bioinformatic analysis
por: Guan, Yibing, et al.
Publicado: (2020)

SUN-388 Immune Checkpoint Inhibitor Nivolumab in Advanced or Recurrent Adrenocortical Carcinoma
por: Akunjee, Munaza, et al.
Publicado: (2019)

Pembrolizumab for metastatic adrenocortical carcinoma with high mutational burden: Two case reports
por: Mota, Jose Mauricio, et al.
Publicado: (2018)

Tumor mutation burden predicts response and survival to immune checkpoint inhibitors: a meta-analysis
por: Wan, Linghong, et al.
Publicado: (2020)

Immature rat testis sustained long-term development using an integrative model
por: Ma, Yubo, et al.
Publicado: (2022)

Germline variants predictive of tumor mutational burden and immune checkpoint inhibitor efficacy
por: Chatrath, Ajay, et al.
Publicado: (2021)

The Efficacy of Tumor Mutation Burden as a Biomarker of Response to Immune Checkpoint Inhibitors
por: Moeckel, Camille, et al.
Publicado: (2023)

Prognostic Role of Tumor Mutational Burden in Cancer Patients Treated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Huang, Taobi, et al.
Publicado: (2021)

Prenatal presentation of an adrenocortical tumor
por: Schwartz, Jeffrey H., et al.
Publicado: (2022)

Was It an Adrenocortical Adenoma or an Adrenocortical Carcinoma? Limitation of the Weiss Scoring System in Determining the Malignant Potential of Adrenocortical Tumor: Report on Two Cases
por: Wong, Cheuk-Lik, et al.
Publicado: (2022)

DNA Repair Gene Mutations as Predictors of Immune Checkpoint Inhibitor Response beyond Tumor Mutation Burden
por: Hsiehchen, David, et al.
Publicado: (2020)

Predicting response to checkpoint inhibitors in melanoma beyond PD-L1 and mutational burden
por: Morrison, Carl, et al.
Publicado: (2018)

Prognostic Factors for Adrenocortical Carcinoma Outcomes
por: Scollo, Claudia, et al.
Publicado: (2016)

Endocrine and Neuroendocrine Tumors Special Issue—Checkpoint Inhibitors for Adrenocortical Carcinoma and Metastatic Pheochromocytoma and Paraganglioma: Do They Work?
por: Jimenez, Camilo, et al.
Publicado: (2022)

A Rare Presentation of Adrenocortical Carcinoma
por: Janquli, Mohammed, et al.
Publicado: (2021)

Checkpoint inhibitor is active against large cell neuroendocrine carcinoma with high tumor mutation burden
por: Wang, Victoria E., et al.
Publicado: (2017)

Tumor Mutational Burden and Efficacy of Immune Checkpoint Inhibitors: A Systematic Review and Meta-Analysis
por: Kim, Jong Yeob, et al.
Publicado: (2019)

Pretreatment neutrophil-to-lymphocyte ratio and mutational burden as biomarkers of tumor response to immune checkpoint inhibitors
por: Valero, Cristina, et al.
Publicado: (2021)

Impact of tumor mutational burden on checkpoint inhibitor drug eligibility and outcomes across racial groups
por: Hsiehchen, David, et al.
Publicado: (2021)

Discussion of tumor mutation burden as an indicator to predict efficacy of immune checkpoint inhibitors: A case report
por: Wu, Mingrui, et al.
Publicado: (2022)

Lynch syndrome-associated chordoma with high tumor mutational burden and significant response to immune checkpoint inhibitors
por: Shinojima, Naoki, et al.
Publicado: (2023)

Adrenocortical Carcinoma Presenting with Signs of Acute Abdomen
por: Symeonidis, Dimitrios, et al.
Publicado: (2013)

Atypical Presentation of Adrenocortical Insufficiency with Anorexia and Jaundice
por: Li, Xiang-Xing, et al.
Publicado: (2018)

Pulmonary Embolism as an Initial Presentation of Adrenocortical Carcinoma
por: Aung, Soe Yu, et al.
Publicado: (2014)

Adrenocortical Carcinoma Presenting as Reversible Dilated Cardiomyopathy
por: Abdulla, Mansoor C.
Publicado: (2018)

Past, Present and Future of Epigenetics in Adrenocortical Carcinoma
por: Ettaieb, Madeleine, et al.
Publicado: (2020)

High and low mutational burden tumors versus immunologically hot and cold tumors and response to immune checkpoint inhibitors
por: Maleki Vareki, Saman
Publicado: (2018)

Screening and Identification of Potential Prognostic Biomarkers in Adrenocortical Carcinoma
por: Xu, Wen-Hao, et al.
Publicado: (2019)

Prognostic Alternative mRNA Splicing in Adrenocortical Carcinoma
por: Liang, Weiwei, et al.
Publicado: (2021)

Clinical and Histopathological Variables and Prognostic Factors of Adrenocortical Carcinoma
por: Sohail, Sara, et al.
Publicado: (2021)

Prognostic roles of hematological indicators for the efficacy and prognosis of immune checkpoint inhibitors in patients with advanced tumors: a retrospective cohort study
por: Zheng, Fei, et al.
Publicado: (2023)

Nonfunctional adrenocortical carcinoma initially presenting as retroperitoneal hemorrhage
por: Kashiwagi, Shinichiro, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_mljbs5q1fmqkp5iic8db5jkit4